腰椎融合手术预防使用塞法林与万科米辛在青素过敏患者
Michael Carter1, Rajkishen Narayanan, Gregory Toci
1Department of Orthopaedic Surgery, Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.
Spine
|October 30, 2024
概括
对于经历腰部融合的轻度青素过敏患者来说,塞法佐林和万科米辛在预防术后感染方面同样有效. 与范科米辛相比,塞法林不会增加过敏反应的风险.
科学领域:
- 传染性疾病 传染性疾病
- 神经外科 神经外科
- 药理学 药理学是指药理学的学科.
背景情况:
- 历史上,青素过敏的患者因担心塞法林的交叉反应性而接受了万科米辛的手术预防.
- 对于经过腰部融合的青素过敏患者中,塞法林与万科米辛的直接比较数据有限.
研究的目的:
- 在接受腰部融合治疗的轻度至中度青素过敏患者中,比较塞法林和万科米辛预防之间的术前和术后感染率.
- 在这个患者群体中,评估药物诱导过敏反应对塞法林的发生率与万科米辛的发生率.
主要方法:
- 在2017年至2022年间,对经历腰部融合治疗的患者进行了回顾性队列研究.
- 分析感染率,药物敏感反应,90天再入院,以及灌和除菌 (I&D) 的需要.
- 与接受塞法林治疗的患者和接受万科米辛预防的患者之间的结局的比较.
主要成果:
- 在塞法佐林和万科米辛组之间,术后感染率没有显著差异.
- 在塞法林组观察到一种轻微的药物诱导皮肤反应;过敏反应没有显著差异.
- 在两个抗生素组之间,90天再入院和I&D手术的比较率.
结论:
- 塞法林和万科米辛在接受腰部融合的青素过敏患者的手术后感染预防方面表现出相似的有效性.
- 与ванкомицин相比,对青素过敏的患有轻度至中度反应的患者对扎林过敏的风险并不增加.
相关概念视频
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:23Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...